Dermatology

Currently, the use of minocycline is limited orally due to some systemic side effects.

The newest indication for the add-on biologic grants it use in children aged 6-11 years old with moderate to severe, uncontrolled atopic dermatitis.

There is no significant association between biologic exposure and the development of melanoma in patients with IBD, rheumatoid arthritis, or psoriasis.

Since the beginning of the COVID-19 pandemic most non-urgent medical appointments have been conducted using telehealth.

With the majority of the scientific research community focused, a COVID-19 vaccine could be on the horizon.

While recent data regarding remdesivir has been positive, there is still a need for medications in pill form to treat COVID-19 infections.

The dermatologist fields questions on possible symptoms and signs of infection that his colleagues have observed.

The Florida-based clinician shares perspective and insight into what should be prioritized or revised in specialty care.

Investigators found 30 mg of apremilast results in a significant reduction in plaque psoriasis patients.

An assessment of survey data show patients with severe depressive or psychological symptoms are more likely to be dissatisfied with their dermatologist.

An expert describes how telehealth can be used during the pandemic.

A dermatologist discusses how to care for patients with psoriasis during the COVID-19 pandemic.

There are currently 14 antiviral medications being tested as possible treatments for COVID-19.

Enjoy our archived discussion between 4 experts on how their specialty is most affected by the pandemic.

A systematic review and meta-analysis show the systemic therapies, as well as a couple investigational biologics, may be superior.

The treatment was initially approved for adults >18 years old.

The free webinar, "Derm Clinical Updates: Keeping Up with COVID-19," will feature a four-expert panel fielding topics on therapies, immunocompromised patients, telemedicine, surgery, and more.

New findings comparing 3 decades of newly approved indications show the proportion of new approvals being supported by just 1 pivotal trial has quadrupled.

The IL-17A-targeting biologic has now been indicated for pediatric plaque psoriasis—marking its fourth indication for patients with chronic diseases.

The findings provide insight into practice, provide a rubric for future studies, and suggest areas to improve resource use and patient care.

Clinical investigator and allergist Jonathan Corren, MD, shares insight on the TSLP inhibitor.

New phase 3 IMMhance findings show durable, sustained effect of the IL-23 inhibitor on a 12-week dose regimen.

New pivotal phase 3 findings support an upcoming sBLA for the IL4 and IL13-targeting agent.

Lisa Stein Gold, MD, of Henry Ford Hospital discusses promising phase 2 data for a new PDE4 inhibitor.

Low fecal intestinal secretory immunoglobin A is commonly found in infants of mothers in the antepartum and persistent depression trajectories.

New data evidences yet another IL-13 targeting biologic for atopic dermatitis.

The Ready, Set, Food! co-founder discusses how research and federal advisory shapes parental understanding of immunotherapy and food allergy prevention.

Patients with psoriatic arthritis are not at an increased risk of cancer, however.